Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

Novo Nordisk continues its efforts to promote the use of genuine, FDA approved GLP-1s while combatting the use of compounded alternatives. This has been a uniquely difficult issue in the weight-loss ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Novo Nordisk (NVO) and Eli Lilly & Co. (NYSE:LLY), the global leaders in obesity medications, are now facing their first ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

MUMBAI: Danish drug giant Novo Nordisk is aiming to hit $1 billion (Rs 8,600 crore) sales in India with its blockbuster weight-loss drug Wegovy (semaglutide) in five to seven years. To reach that ...